Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers

91

LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE–The CTP-692 safety assessment in the single- and multiple-ascending dose trials showed that the drug was well tolerated over the dose ranges tested.

 

 

http://www.businesswire.com/news/home/20190612005122/en/Concert-Pharmaceuticals-Reports-Positive-Results-Phase-1/